Henoch-Schonlein Purpura - Sally Daughtrey, ND (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Daughtry explains Henoch-Schonlein (HSP), its triggers and complications (such as serious hidden infections often missed initially), and the use of Low Dose Naltrexone in treating HSP. Dr. Daughtry gives an in-depth look into one pediatric case she treated successfully with LDN.

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)

Mold toxicity - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.

Early Biomarkers of a Brain on Fire - Tom O’Bryan, DC, CCN, DACBN (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Mark Cooper, PhD - LDN, Neuroinflammation, and Movement Disorders (2018 Conference) (LDN, low dose naltrexone)

Yoon Hang "John" Kim, MD - Treating chronic pain with low dose naltrexone and ultra low dose naltrexone (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Saturday Afternoon Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Samyadev Datta, MD - Pharmacology of Low dose Naltrexone in Chronic Pain Management (2019 Conference) (LDN, low dose naltrexone)

Samyadev Datta, MD discusses LDN and ultra-low dose naltrexone (ULDN) to treat chronic pain and inflammatory/autoimmune conditions. He presents on the history and pharmacology of naltrexone, forms in which LDN can be prepared. Several case studies on pain are presented

Dana Keaton, ND - The scope of patient selection for LDN (2019 Conference) (LDN, low dose naltrexone)